Boston-based venture capital firm SV Life Sciences is working on its sixth fund, with a fundraising target of $400 million, according to a Form D filing on the U.S. Securities and Exchange Commission’s website. The firm invests in biotech, medical devices, health IT and healthcare services.
In a phone interview, CFO Denise Marks told MedCity News the firm’s previous fund closed out in 2010 with $523 million. The initial target then was also $400 million. Although it’s done making initial deals with the fifth fund, it has a reserve for any follow-on deals for companies that haven’t yet exited, Marks said.
Image: https://www.flickr.com/photos/76657755@N04/6881485010
